![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » REVATIO APPROVED TO TREAT RARE AND INCURABLE DISEASE
REVATIO APPROVED TO TREAT RARE AND INCURABLE DISEASE
Pfizer Canada announced that it has received Health Canada approval for Revatio (sildenafil citrate), an important new treatment for pulmonary arterial hypertension (PAH), a rare and incurable vascular disease. Sildenafil citrate is also the active ingredient in Viagra, Pfizer's revolutionary treatment for erectile dysfunction, which has been used by more than 27 million men worldwide since it was first introduced in 1998. CNW Group (http://www.newswire.ca/en/releases/archive/August2006/22/c7333.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct